Dr. Abbas discusses the common drawbacks of using conventional methods for ADME studies that can misinform the candidate selection process and dosage figures. He talks about how emerging complementary technologies, such as organ-on-a-chip (OOC), offer human-relevant in vitro preclinical data, and how using OOC can support the determination of human bioavailability to support drug dosing regiments, reduce side effects, and potentially recover flawed therapeutic candidates.